like face disrupt coronaviru
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim
price data apr
rate updat apr
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
foundat remain solid base strong cash flow
gener basket divers drug compani larg size
confer signific competit advantag develop new
drug unmatch heft combin broad portfolio
patent-protect drug help build wide econom
moat around busi
size establish one largest economi scale
pharmaceut industri busi drug develop
need lot shot goal success financi
resourc establish research power support
develop new drug also mani year
struggl bring import new drug launch
sever potenti blockbust cancer heart diseas
commit postapprov studi provid
salespeopl armamentarium data market
campaign lead salesforc emerg
countri posit compani benefit dramat
increas wealth nation brazil russia india china
turkey
entrench industri leader face challeng
near term loss patent protect sever drug
weigh futur growth particular recent patent
loss neurosci drug lyrica weigh near-term growth
howev recent decis divest off-pat divis
creat new compani combin drive
acceler growth remain innov busi
believ oper withstand addit
gener competit acquisit wyeth help
insul one particular patent loss follow
merger much stronger posit vaccin industri
pneumococc vaccin prevnar vaccin tend
resist gener competit manufactur
complex rel lower price
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note ep calcul divid net earn share outstand
one world largest pharmaceut firm annual sale
billion also spend lead amount research
develop close billion annual histor sold mani
type healthcar product chemic prescript drug
vaccin account major sale top seller includ pneumococc
cardiovascular treatment eliqui immunolog drug xeljanz sell
product global intern sale repres close
total sale within intern sale emerg market major
contributor repres fifth total compani sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
slightli reduc fair valu estim pfizer
base like coronaviru disrupt
drug portfolio specif expect new drug
launch oncolog drug xtandi mektovi braftovi
along cardiovascular drug vyndaqel stagnat bit
patient doctor less inclin tri new
treatment result million total sale less
sale drug collect also expect
entrench drug eliqui atrial fibril ibranc
breast cancer bring fewer new patient peopl
avoid check ailment cut close million
total sale addit expect vaccin
sale prevnar fall especi adult patient
older patient tri avoid doctor offic hospit due
concern around contract coronaviru
look core busi expect
annual sale growth next three year includ
acquisit new drug off-set gener competit
howev bottom line project slightli healthier
annual growth rate next three year
cost-cut plan share buyback take shape
model unannounc acquisit acquisit hold
potenti acceler compani growth rate
long term believ diversifi line-up drug
reduc volatil earn anticip
restructur effort elimin duplic
posit help allevi margin pressur
high-margin product lose exclus cost capit
perspect estim cost equiti
weight averag cost capit line peer
larg base low volatil cash flow
divers product portfolio inelast demand rate
uncertainti low scenario analysi assum
base-cas fair valu estim bull-cas fair
valu estim probabl bear case
probabl project fair valu rel
base case scenario analysi show minor varianc
henc low uncertainti rate key factor affect
scenario analysi includ degre success
brand drug pipelin along magnitud market
pressur current market drug within group
recent launch drug import driver
valuat ibranc cancer addit unknown
magnitud biosimilar competit
immunolog diseas weigh certainti
compani lastli ad potenti
healthcar polici reform relat drug price bear
case creat addit pressur
enbrel
patent economi scale power distribut
drug carri strong price power enabl firm
gener return invest capit excess cost
capit patent give compani time
develop next gener drug gener
competit aris addit hold
diversifi product portfolio
product
concentr compani largest product prevnar
repres total sale howev
expect typic gener competit vaccin due
complex manufactur rel low price
product expect new product mitig
eventu gener competit key drug also
pfizer oper structur allow cost-cut follow
patent loss reduc margin pressur lost
line creat enorm cash flow need fund
averag million develop cost per new drug
addit compani power distribut network
set compani strong partner smaller drug
compani lack resourc entrench
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
turn macroeconom environ
sever headwind make solid strateg move
address challeng neg side
risk-sensit food drug administr
gener approv safe drug drug
high-ne area cancer also managed-car
organ pharmaci benefit manag
consolid past decad use
grow size demand lower drug price reduc
coverag less innov drug forc drug firm
push true innov reduc power pfizer
distribut network govern
evalu compar effect program
aggress price negoti rais bar futur
innov face sever headwind
pipelin focus innov treatment area
unmet medic area cancer payer
coverag price power remain strong outsid
pipelin compani strong entrench vaccin
consum healthcar give firm relief
pressur drug group
consum vaccin franchis creat ad layer
competit advantag stem brand power
consum healthcar manufactur cost advantag
vaccin divis recent creat consum
healthcar joint ventur glaxosmithklin could
lead eventu divest unit potenti
divest materi impact
believ face stabl moat trend next
five year compani major patent loss repres
total sale howev strong pipelin
combin stabl current market drug lead
modest growth annual period
exclud acquisit also patent exposur
face biolog shouldnt declin fast
small molecul patent expir offset
patent loss pipelin side expect well
billion peak annual sale three new drug includ
recent launch cancer drug ibranc xtandi
vyndaqel rare cardiovascular diseas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
pipelin product improv sever
changer rare diseas area
oth stock support dividend yield
expect steadi cash flow support dividend
decis divest off-pat divis
result faster grow innov compani
research
given import continu invest
oalthough compani worst
patent cliff still face recent major patent loss
lyrica
osever late-stag pipelin drug
enter crowd market may limit share gain
due delay entri
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
hold strong financi posit larg
degre flexibl end debt/capit
stood debt/ebitda ratio
suggest remain solid financi foot
major cash flow deriv divers portfolio
product dont expect high degre volatil
futur earn like continu make
acquisit believ rel easili take debt
fund larger deal
polici chang govern increasingli stringent
fda stronger managed-car pharmaci benefit
manag negoti power new drug develop
becom challeng sever diseas area
pharmaci benefit manag grown past
two decad power entiti negoti lower
drug price although remot litig risk remain
evidenc merck high settlement cost involv
vioxx also sever pipelin drug reach
market behind competitor may increas risk
commerci failur put downward price
pressur drug clinic data lack posit
differenti brand competit front merck
work develop next-gener pneumococc
vaccin cover valent could threaten
prevnar cover two fewer valent howev
overal view uncertainti low base
low volatil cash flow divers product portfolio
inelast demand
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ceo/chairman board/
repres date owner name posit common share held report holder issuer
new york mellon corp
share
fund
share
fund
rate stewardship standard
compani made mani poor capital-alloc decis
past decad current manag team
appear focus significantli better use cash
includ share buyback dividend also decis
sell nutrit anim healthcar busi
appear creat valu sharehold also like
strateg decis form joint ventur
glaxosmithklin consum healthcar front give
firm scale marketplac front
recent acquisit array look strateg sound
price look reason howev high price paid
mediv fail attempt acquir astrazeneca
allergan concern
begin albert bourla becam ceo
follow sever posit take
leadership role bourla chief oper offic
led innov health divis bourla bring
year experi top posit
bourla vast experi help decision-mak
one first major decis bourla made divest
off-pat busi combin
remain innov busi stronger
posit grow top-lin sale also newli creat
off-pat busi increas scale
import highli competit gener busi
overal view corpor restructur modest
posit allow innov off-pat
compani focu drive better return
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
defens natur healthcar firm offer
concern around global recess due coronaviru
disrupt weigh global market
defens natur healthcar hold rel
basi dont expect signific chang
healthcar moat rate may make downward
adjust valuat healthcar account
near-term challeng expect modest chang
rel recent stock price movement base case
call strong econom rebound follow
recess modest impact
healthcar valuat given defens natur
compani howev coronaviru pandem exert
sustain impact economi significantli higher
number patient unemploy uninsur
underinsur could reduc healthcar demand
greater extent expect govern effort reduc
near-term hit keep harder-hit industri
busi effect treatment emerg
near-term effect coronaviru expect critic
therapi crowd elect procedur new
product non-critical-car product fewer elect
procedur weigh devic maker servic
focus covid-specif case could reduc
profit health insur brand drug firm
alreadi focus specialti drug expect less impact
industri drug administ hospit could
still feel crowd coronaviru patient also
clinic develop timelin probabl face
delay due coronaviru disrupt like slow
new product launch addit coronaviru
impact credit market could weigh heavili
indebt compani hospit firm
compani recent complet major acquisit
outlook coronaviru global
economi well potenti new treatment
coronaviru pleas see
widespread diseas drug pipelin progress
outlook chang drug price polici
initi result super tuesday democrat primari
show increas support former vice presid biden
whose nomin would reduc likelihood signific
drug price polici chang line
expect dont expect major chang fair
valu estim moat rate drug biotech
industri base result continu view
industri under-valued averag
due partli excess concern around potenti major
drug polici chang note elect result
bigger impact healthcar insur servic
relief ralli health insur servic provid
drug side movement toward moder
democrat biden like mean minor drug polici
chang reduc chanc medicar
scenario champion biden key oppon sen
berni sander would like significantli reduc
drug price negoti power one-pay
system elect support shift toward biden
believ like chang drug price polici
reform center around senat bill prescript drug
price reduct act pdpra howev still believ
propos hold less chanc pass base
mix level support parti havent
includ passag bill model howev
pass estim aggreg hit brand
drug sale medicar inflat price cap part
redesign propos bill believ drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
biotech industri could adapt headwind
minor impact cash flow partli cost cut
increas volum base lower price mandat
bill importantli bill would limit out-of-pocket
payment patient medicar would like help
appeas demand lower drug price
potenti drug polici chang key element
esg analysi drug firm pleas see recent
healthcar observ esg risk affect moat
pharma morningstar
post slightli weak fourth quarter guidanc
look solid innov drug group jan
report fourth-quart result slightli
expect partli due higher-than-expect
market expenditur dont expect major
chang fair valu estim base result
quarter sale new drug mitig gener
pressur face firm lead oper sale
declin exclud shift consum product joint
ventur abil off-set gener pressur new
decis divest older drug platform upjohn
remain part posit
stronger growth guidanc remain
innov biopharma group slightli higher
project look achiev expect strong
growth cardiovascular drug eliqui rare heart
diseas drug vyndaqel along cancer drug ibranc
braftovi mektovi help achiev guidanc
believ heavi market expens quarter
support new drug
look ahead pipelin look pois deliv
strong data expect posit data pfizer new
pneumococc vaccin offer broader coverag rel
prevnar merck competit vaccin also
data readout ibranc early-stag breast cancer
divest older drug platform remov
typic sale drag face year pressur
sale growth quarter includ gener competit
neurolog drug lyrica shift drug
expect new drug platform
need off-set major patent loss near term
combin platform pfizer
older drug face pressur grow profit margin
pfizer older drug strong enabl robust cash
concern around price pressur
pharmaceut believ larg well posit
portfolio vaccin drug volum
like larger driver growth rel price
next sever year pfizer price posit
aspect environment social govern
includ legal issu pleas see recent healthcar
observ esg risk affect moat valuat
pharma morningstar sustainalyt offer
sustainalyt esg risk methodolog
point opportun pharma/biotech jan
sustainalyt
own
collabor broaden deepen
esg analysi incorpor environment social
govern factor valuat analysi
pharma focus
materi esg issu social realm think
firm expos esg risk morningstar
conclud valuation-affect esg risk brand
drug firm center price risk larg litig
provid comprehens evalu support
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
mostli wide moat rate industri
larg drug biotechnolog compani
overal see under-valued name roch
biomarin lowest exposur esg-rel
strategi focu sever diseas lower price
pressur includ base case alreadi factor much
potenti headwind intern benchmark
price could test medicar part
biomarin global price strategi rare-diseas drug
well seriou natur condit limit futur
price litig risk despit high price tag
medicar exposur minim
import action propos
human servic juli propos rule
releas fda decemb dont view
plan major driver lower drug price think
implement chang would difficult
practic hard reconcil safeti provis
part feder track-and-trac system stop
counterfeit drug ensur enough drug-firm suppli low
price canada anoth concern drug firm could
limit distribut limit re-import also canada would
like support plan low drug price would
like face rise pressur support price
also like sanofi
valuat esg risk johnson johnson eli lilli look
least compel us base litig risk
valuat look under-valued
implement scope drug target potenti
re-import limit exclud drug biolog
inject drug drug subject fda risk evalu
mitig strategi rem drug group repres
core area focu new drug reach market
detail analysi price litig issu
top pharma name
coverag see januari
healthcar observ esg risk affect moat
pharma morningstar
trump propos drug reimport look limit
potenti lower drug price dec
trump administr move allow drug import
canada look challeng implement
limit scope dont expect major chang
fair valu estim drug biotechnolog
industri view administr move driven
polit motiv anoth elect cycl draw
near rather major structur shift influenc drug
price continu view price power drug
strong central pillar support moat rate
congress support drug re-import past
safe implement propos limit
enact expect similar limit around
recent propos given complex distribut
differ drug label countri see poor
prospect wide use drug re-import
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued within
report highlight impact enact chang
drug payment increas discount
medicar part doughnut hole sale also review
depth drug polici propos council
econom advisor budget
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
colorect cancer major opportun
complet review pipelin current
report moat remain secur innov counter
price gener headwind acceler
report solid third quarter innov drug
look posit long-term growth oct
report third-quart result ahead capiq
consensu expect dont expect major
chang fair valu estim base minor
out-performance continu view compani
under-valued market like underappreci
firm recent launch drug late-stag pipelin
also increas convict firm wide moat
divest
quarter total sale fell oper year
year biopharma segment increas
import segment remain part pfizer
upjohn segment
establish older drug
expect moder biopharma segment
growth expect recent launch drug continu
drive biopharma growth close annual
five-year period upjohn divest line
manag expect driver growth includ
cancer drug ibranc xtandi hold good
potenti expand new indic ibranc like
report import earli adjuv breast cancer data
also cardiovascular drug eliqui well posit
continu gain older treatment warfarin
base lead efficaci data surprisingli immunolog
drug xeljanz continu post excel growth
 despit safeti concern like show need
altern treatment rheumatoid arthriti
pipelin side make solid stride
importantli firm next-gener pneumococc
vaccin show good data infant patient popul
look margin behind merck compet
late-stag vaccin reach market
pfizer vaccin cover five valent
view franchis larg secur also view
strong data cancer drug braftovi mektovi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
